Cargando…
Progression-free survival of up to 8 months of an advanced intrahepatic cholangiocarcinoma patient treated with apatinib: a case report
Intrahepatic cholangiocarcinoma (ICC) arises from the biliary epithelium and is a relatively rare and highly fatal neoplasm. The prognosis is poor, and survival is limited to a few months. Here, we report a case of advanced ICC that was successfully treated with apatinib, a new oral tyrosine kinase...
Autores principales: | Ma, Fu-Chao, Yu, Qian, Zeng, Zhi-Ming, He, Rong-Quan, Mo, Chao-Hua, Zhong, Jin-Cai, Ma, Jie, Feng, Zhen-Bo, Chen, Gang, Hu, Xiao-Hua |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5677377/ https://www.ncbi.nlm.nih.gov/pubmed/29138576 http://dx.doi.org/10.2147/OTT.S146051 |
Ejemplares similares
-
Apatinib inhibits VEGF signaling and promotes apoptosis in intrahepatic cholangiocarcinoma
por: Peng, Hong, et al.
Publicado: (2016) -
Efficacy and Safety of Apatinib Treatment for Patients with Advanced Intrahepatic Cholangiocarcinoma
por: Lin, Guohe, et al.
Publicado: (2020) -
Apatinib as non-first-line treatment in patients with Intrahepatic Cholangiocarcinoma
por: Mao, Jinzhu, et al.
Publicado: (2021) -
Efficacy and Safety of Apatinib in Treatment of Unresectable Intrahepatic Cholangiocarcinoma: An Observational Study
por: Hu, Yubin, et al.
Publicado: (2020) -
The diagnostic and prognostic value of UBE2T in intrahepatic cholangiocarcinoma
por: Yu, Hua, et al.
Publicado: (2020)